BioCentury | Jan 25, 2020
Product Development

A milestone year for Roche’s CNS gambit could kick off its plan for the decade

A ramped up focus on CNS that has been long in the making could start to pay off this year for Roche, which has two programs slated for launch and four others with late-stage readouts...
BC Extra | Jan 10, 2020
Financial News

Jan. 9 Financial Quick Takes: Closes for two royalty funds; plus Apellis leads follow-on trio, Element, Omniome, Hinova, Emergex, Tscan, Calliditas

HealthCare Royalty, Sagard close royalty funds  HealthCare Royalty Partners closed its HealthCare Royalty Partners IV fund at $1.8 billion. The firm also promoted four team members to managing director: Carlos Almodóvar, head of IR; Shin...
BC Extra | Jan 8, 2020
Clinical News

Apellis readies to compete with Soliris in PNH based on Phase III data

Apellis’ paroxysmal nocturnal hemoglobinuria candidate has beaten Soliris head-to-head on hemoglobin level improvement. Despite some ambiguity on how FDA will see the data, the company believes pegcetacoplan has a strong case for approval and could...
BioCentury | Jan 4, 2020
Finance

Politics aside, 2020 could be a good year for bringing back generalists

After largely being out of biotech stocks for four years, generalist investors have shown signs that they are ready to dip their toes again in 2020. The fourth quarter surge, and a spate of 2019...
BC Extra | Dec 9, 2019
Company News

Novartis downsizing internal efforts on CAR T in solid tumors

Novartis is pivoting away from internal development of CAR Ts in solid tumors, it said Thursday at its R&D day. The company is, however, pressing forward with the modality via partnerships, and plans to use...
BC Extra | Nov 23, 2019
Clinical News

A first-in-class approval for rare anemia could be next step for Sanofi’s sutimlimab

Having met the primary endpoint in the pivotal CARDINAL trial, Sanofi’s sutimlimab could become the first approved therapy for primary cold agglutinin disease. According to the company, the data are the first Phase III results...
BC Extra | Nov 6, 2019
Company News

Biogen expanding biosimilars deal for eye therapies, anti-TNFs

As it continues to rely on biosimilars as a growth driver, Biogen has expanded its deal with Samsung Bioepis to include two new ocular biosimilars in certain major markets, as well as rights in China...
BC Extra | Oct 21, 2019
Company News

Oct. 21 Company Quick Takes: Vertex's triplet gains FDA approval; plus Bavarian Nordic-GSK, Farxiga, Ultomiris, Stelara

FDA approves Vertex's triplet for CF  Vertex Pharmaceuticals Inc. priced triple combination cystic fibrosis therapy Trikafta elexacaftor/ivacaftor/tezacaftor at an annual wholesale acquisition cost of $311,503 after FDA approved the drug on Monday, almost five months...
BioCentury | Oct 19, 2019
Finance

Achillion’s journey to $1 billion

Alexion’s proposed takeout of Achillion would complete a 21-year journey that saw the latter evolve from an antiviral play into a complement pathway company. For Alexion, it represents the next step in its quest to...
BC Extra | Oct 17, 2019
Company News

Deal streak continues for Alexion as Achillion’s story hits $930M high note

Alexion’s proposed takeout of Achillion would complete a 21-year journey that saw the latter evolve from an antiviral play into a complement pathway company. For Alexion, it represents the next step in its quest to...
Items per page:
1 - 10 of 530